Semaglutide facts, myths, and online claims
Semaglutide is a GLP-1 receptor agonist. As Ozempic it is used with diet and exercise for type 2 diabetes and to lower heart and kidney risk in that group. As Wegovy it is used for weight reduction in adults and children 12 and older, and to lower heart risk in adults with heart disease. Most forms are a once-weekly injection under the skin, started at a low dose and raised in steps. Rybelsus and Wegovy tablets are taken once a day.
Below: what the FDA label and NIH sources establish, what people say about Semaglutide in public forums set next to the evidence, the misconceptions that come up most, and the questions people ask. Every line links to where it came from.
Established facts (8)
Ozempic is approved as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes, to reduce major cardiovascular events in those with known heart disease, and to slow kidney disease progression in those with chronic kidney disease.
Wegovy injection is approved for weight reduction in adults and children aged 12 and older with obesity, for adults with overweight plus a weight-related condition, to reduce major cardiovascular events in adults with heart disease, and, under accelerated approval, for MASH liver disease with moderate to advanced fibrosis.
Dosing starts at 0.25 mg once weekly for 4 weeks, then rises in 4-week steps. Ozempic tops out at 2 mg weekly. Wegovy injection reaches a maintenance dose of 2.4 mg (or 1.7 mg) weekly by week 17.
The label carries a boxed warning: in rodents semaglutide causes thyroid C-cell tumors, and it is unknown whether it does so in humans. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
In Ozempic trials the most common adverse reactions were nausea (15.8 to 20.3 percent), vomiting, diarrhea, abdominal pain, and constipation. In Wegovy trials headache and fatigue also occurred in at least 5 percent, and stomach effects were most frequent during dose escalation.
Acute pancreatitis, including fatal cases, has been observed with semaglutide, and Wegovy treatment is associated with an increased occurrence of gallstones and gallbladder inflammation.
In the SELECT trial of adults with heart disease and overweight or obesity, major cardiovascular events occurred in 6.5 percent on Wegovy versus 8 percent on placebo over the study, a hazard ratio of 0.80.
Semaglutide tablets are taken on an empty stomach on waking, with no more than 4 ounces (120 mL) of water, followed by a wait of at least 30 minutes before eating, drinking, or taking other medicines.
What people say online (6)
Claims collected from public forums and review sites, quoted the way people put them. They are listed so the evidence can sit next to them, not because they are true. Status reflects what the cited studies and labels show as of 2026-09-07.
- Partly supported
"The weight comes back lightning quick once you stop, plus a few extra pounds."
In the STEP 1 trial extension, people who lost 17.3 percent of body weight on semaglutide regained about two-thirds of it in the year after stopping, ending 5.6 percent below where they started. Regain is common and substantial, but the average person did not end up heavier than baseline.
- Partly supported
"Hair loss is real with Wegovy, it started around month six."
The Wegovy label lists hair loss in 3 percent of adults versus 1 percent on placebo. A 2026 survey of 152 GLP-1 users found shedding was far more common and tracked with the amount of weight lost, which suggests rapid weight loss itself is a major driver.
- Partly supported
"It stops being effective right when it is time to go up a dose."
The approved schedule raises the dose every 4 weeks, and trials show weight loss slows and levels off over roughly a year. When the drug was withdrawn in the STEP 1 extension, weight returned, which indicates it was still acting even after loss had plateaued.
Seen on Drugs.com reviews (weight loss)Evidence FDA label, Wegovy, STEP 1 extension (PMC) - Unproven
"Injecting in the thigh instead of the stomach made the nausea disappear overnight."
The label allows injection in the abdomen, thigh, or upper arm and states that similar drug exposure is achieved at each site. No controlled study has compared side effects by injection site, so reports of relief after switching are anecdotal.
Seen on Drugs.com reviews (nausea), Drugs.com reviews (Ozempic)Evidence FDA label, Ozempic - Partly supported
"Ozempic gave me gastroparesis after three months."
Semaglutide slows stomach emptying by design, and the label's postmarketing section lists ileus, intestinal obstruction, and severe constipation. Slowed emptying is expected and usually eases; lasting stomach paralysis is reported but its frequency is not established.
Seen on Drugs.com reviews (Ozempic)Evidence FDA label, Ozempic - Partly supported
"Injection day wipes me out, I am tired every time I take it."
Fatigue was reported by at least 5 percent of Wegovy trial participants, so tiredness is a recognized effect. Whether it clusters on the injection day has not been studied, and trial data do not describe timing within the week.
Seen on Drugs.com reviews (Wegovy)Evidence FDA label, Wegovy
Common misconceptions (4)
Myth Semaglutide causes suicidal thoughts.
Reality In January 2026 the FDA reviewed 91 placebo-controlled trials with about 108,000 patients and a 2.2 million person cohort study and found no increased risk of suicidal thoughts or behavior. It asked for the warning to be removed from Wegovy labeling.
Myth Ozempic and Wegovy are different drugs.
Reality Both contain the same molecule, semaglutide, approved for different uses at different doses. Because they are the same drug, the label says using Wegovy together with other semaglutide products or any other GLP-1 receptor agonist is not recommended.
Myth Semaglutide is proven to cause thyroid cancer in people.
Reality The boxed warning is based on thyroid C-cell tumors in rodents. The label states it is unknown whether semaglutide causes these tumors in humans. The warning leads to a contraindication for people with a history of medullary thyroid carcinoma or MEN 2.
Myth Semaglutide tablets can be taken with breakfast like any other pill.
Reality The tablet is taken on an empty stomach on waking with no more than 4 ounces of water, followed by at least 30 minutes before food, drink, or other medicines, because food and larger volumes of water reduce how much is absorbed.
Questions people ask (7)
- How does semaglutide work?
- It copies the gut hormone GLP-1. In diabetes it helps the pancreas release insulin when blood sugar is high. It also slows stomach emptying and lowers appetite, which is why it leads to weight loss in people with or without diabetes.
- How long does semaglutide stay in your system?
- The elimination half-life is about one week. The label states semaglutide remains in the circulation for about 5 weeks after the last dose, which is why pregnancy guidance and some surgery guidance count in weeks rather than days.
- What happens if a weekly dose is missed?
- For diabetes, MedlinePlus says a missed dose can be given within 5 days; after that it is skipped. For weight loss or MASH the window is 2 days (48 hours). The next dose then stays on the usual day.
- Do the stomach side effects get better?
- Nausea, diarrhea, vomiting, constipation, and abdominal pain are the most common reactions. The Wegovy label notes they were most frequently reported during dose escalation, which is the first 16 weeks, and many people find them milder once on a steady dose.
- Does semaglutide reduce alcohol cravings?
- A 9-week randomized trial of 48 adults with alcohol use disorder found low-dose semaglutide reduced alcohol craving and drinks per drinking day compared with placebo. The authors called it initial evidence and said larger trials are needed. It is not an approved use.
- Can semaglutide be used in pregnancy?
- The Wegovy label says to discontinue it when pregnancy is recognized, and to discontinue at least 2 months before a planned pregnancy because of the long half-life. Available data are limited, and weight loss offers no benefit during pregnancy.
- Is semaglutide a shot or a pill?
- Both. Ozempic and Wegovy injections are given under the skin once a week on the same day each week. Rybelsus and Wegovy tablets are taken once daily. Pens are stored in the refrigerator and must not be frozen.
Not medical advice. This page summarizes public sources and public opinion about Semaglutide. It cannot see your dose, your other medicines, or your history. A pharmacist or prescriber can.